Preferred Label : Rituximab;

NCIt synonyms : C2B8 Monoclonal Antibody; Monoclonal Antibody IDEC-C2B8; Chimeric Anti-CD20 Antibody; IDEC-C2B8 Monoclonal Antibody; Rituximab Biosimilar CT-P10; Rituximab Biosimilar BI 695500; Rituximab Biosimilar IBI301; Rituximab Biosimilar SAIT101; Rituximab Biosimilar RTXM83; Rituximab Biosimilar ABP 798; Rituximab Biosimilar PF-05280586; Rituximab Biosimilar GB241; rituximab biosimilar TQB2303; Rituximab ABBS; Rituximab Biosimilar SIBP-02; Rituximab ARRX; Rituximab PVVR;

NCIt related terms : Rituxan; Rituximab-abbs; Rituximab-pvvr; Rituximab-arrx; Rituximab-rixi; Rituximab-rite; Rituximab-blit; Rituximab-rixa;

NCIt definition : A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04);

Alternative definition : NCI-GLOSS: A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.;

UNII : 4F4X42SYQ6;

CAS number : 174722-31-7;

Drug name : MabThera; Rituxan; Truxima; Ruxience; Riabni; Mabtas; Ikgdar; Blitzima; Riximyo; Rixathon; Ritemvia;

Molecule name : IDEC-102; IDEC-C2B8; BI 695500; CT-P10; PF-05280586; PF 05280586; ABP 798; Rituximab Biosimilar JHL1101; RTXM-83; IDEC 102; RTXM 83; BI-695500;

NSC code : 687451;

ChEBI ID : CHEBI:64357;

Codes from synonyms : CDR0000505945; CDR0000045525; 70306; 48315; 446; 445; 125360; 125359; 125358; 125356;

Details


Keyword's position in hierarchy(ies) : arborescence

Main resources

You can consult :


https://www.rheuma-net.ch/fr/doc/rituximab-2/viewdocument/359
2024
Switzerland
guideline
rituximab
Rituximab
Rituximab
Background Treatment

---
https://pgtmsite.files.wordpress.com/2024/01/rituximab_es_21mar14.pdf
2014
Canada
drug information
disease
lymphoma, Non-Hodgkin
malignant lymphoma, nos
NCI CTEP SDC Non-Hodgkin Lymphoma Sub-Category Terminology
patients
lymphoma
Patient
has patient
Raw
Maintenance Therapy
Childhood Non-Hodgkin Lymphoma
interviews as topic
Rituximab
rituximab
Follicle
interview
Rituximab
DUSP4 wt Allele
GDC Type Terminology
Adult Non-Hodgkin Lymphoma

---
https://pgtmsite.files.wordpress.com/2024/01/rituximab_rum_pgtm_rapp_final_20100315.pdf
2010
Canada
drug information
Use
Rituximab
Review
rituximab
Rituximab
Analyzed
Analysis

---
https://pgtmsite.files.wordpress.com/2024/01/rituximab_arthrite_rhumat_es_20080515.pdf
2008
Canada
drug information
Rituximab
Rheumatoid Arthritis
arthritis, rheumatoid
rituximab
Rituximab
Polyarthritis

---
https://pgtmsite.files.wordpress.com/2024/01/rituximab_folliculaire_entretien_pgtm_20071108.pdf
2007
Canada
drug information
Rituximab
interview
interviews as topic
Rituximab
Reviewing
Follicle
Maintenance Clinical Trial Setting
rituximab

---
https://pgtmsite.files.wordpress.com/2024/01/rituximab_ad_et_rum_pgtm_20060209.pdf
2006
Canada
drug information
Analysis
Review
Rituximab
Use
Analyzed
Rituximab
rituximab

---
https://pgtmsite.files.wordpress.com/2024/01/rituximab_folliculaire_pgtm_20060209.pdf
2006
Canada
drug information
Follicle
Rituximab
Ligne
rituximab
Rituximab
Line Unit of Length
Long Interspersed Element

---
Nous contacter.
29/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.